Drug Profile
Meloxicam/rizatriptan - Axsome Therapeutics
Alternative Names: AXS 07; MoSEIC™ meloxicam and rizatriptan; MoSEIC™ meloxicam/rizatriptanLatest Information Update: 08 Jan 2024
Price :
$50
*
At a glance
- Originator Axsome Therapeutics
- Class 2 ring heterocyclic compounds; Amides; Analgesics; Antimigraines; Antipyretics; Antirheumatics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Small molecules; Thiazines; Thiazoles; Tryptamines
- Mechanism of Action Cyclo-oxygenase 2 inhibitors; Serotonin 1B receptor agonists; Serotonin 1D receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Migraine
Most Recent Events
- 04 Jan 2024 Axsome Therapeutics plans to resubmit the New Drug Application (NDA) for AXS 07 for the treatment of migraine in the first half of 2024
- 22 Apr 2023 Pooled efficacy and adverse events data from a phase III MOMENTUM and INTERCEPT trial in Migraine presented at the 75th Annual Meeting of the American Academy of Neurology 2023 (AAN-2023)
- 01 Sep 2022 Axsome Therapeutics initiates a phase III EMERGE trial in Migraine (Treatment-naive) in USA (PO)